Insmed Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
11,500.00
-
-
-
-
9,835
Cost of Goods Sold (COGS) incl. D&A
-
1,073.00
1,982.00
2,438.00
2,901.00
7,249
Gross Income
-
1,073.00
1,982.00
2,438.00
2,901.00
2,586
SG&A Expense
65,835.00
86,292.00
115,511.00
170,962.00
186,019.00
309,924
EBIT
55,015.00
87,365.00
117,493.00
173,400.00
188,920.00
307,338
Non Operating Income/Expense
33.00
141.00
33.00
119.00
300.00
602
Interest Expense
2,412.00
2,415.00
2,889.00
3,498.00
5,925.00
25,472
Pretax Income
57,294.00
89,581.00
120,154.00
176,175.00
192,921.00
324,076
Income Tax
1,221.00
10,422.00
1,971.00
98.00
272.00
201
Consolidated Net Income
56,073.00
79,159.00
118,183.00
176,273.00
192,649.00
324,277
Net Income
56,073.00
79,159.00
118,183.00
176,273.00
192,649.00
324,277
Net Income After Extraordinaries
56,073.00
79,159.00
118,183.00
176,273.00
192,649.00
324,277
Net Income Available to Common
56,073.00
79,159.00
118,183.00
176,273.00
192,649.00
324,277
EPS (Basic)
1.60
1.84
2.02
2.85
2.89
4.22
Basic Shares Outstanding
34,980.00
43,095.00
58,633.00
61,892.00
66,576.00
76,889
EPS (Diluted)
1.60
1.84
2.02
2.85
2.89
4.22
Diluted Shares Outstanding
34,980.00
43,095.00
58,633.00
61,892.00
66,576.00
76,889
EBITDA
54,335.00
86,292.00
115,511.00
170,962.00
186,019.00
302,512
Non-Operating Interest Income
166.00
58.00
261.00
604.00
1,624.00
10,341

About Insmed

View Profile
Address
10 Finderne Avenue
Bridgewater New Jersey 08807
United States
Employees -
Website http://www.insmed.com
Updated 07/08/2019
Insmed, Inc. operates as a biopharmaceutical company focused on developing and commercializing inhaled therapies for patients battling serious lung diseases that are often life threatening. It focuses on the development and commercialization of ARIKAYCE or liposomal amikacin for inhalation (LAI), for at least two identified orphan patient populations: patients with nontuberculous mycobacteria lung disease and cystic fibrosis patients with Pseudomonas aeruginosa lung infections. The company was founded on November 29, 1999 and is headquartered in Bridgewater, NJ.